Fiscal Year Earnings Estimate on Albany Molecular Research, Inc.(AMRI)

Albany Molecular Research, Inc.(AMRI): For the most recent quarter end, Albany Molecular Research, Inc. reported Annual Earnings of $0.3. Based on the filings, last years Annual Earnings was, $0.75. For the most recent quarter end, AMRI reported a surprise Earnings per Share of -37.5% . The consensus estimate for current quarter is $0.25 and for the current fiscal year, the estimate is $1.3. For the Next fiscal year, the estimate is $1.38 based on the consensus. Albany based Albany Molecular Research, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on May 09, 2017.

Albany Molecular Research, Inc. has received $0.25 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $0.22 while the top line estimate is $0.28 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 257.14%. Albany Molecular Research, Inc. results fell short with a surprise EPS of -37.5% or $-0.18. The Actual EPS was $0.3 compared to the Estimated EPS of $0.48 during its most recent quarterly earnings. According to the corporate earnings calendar, Albany Molecular Research, Inc. will release next earnings on May 09, 2017 with an estimated EPS consensus of $0.25. Based on the consensus of stock financial advisors the stock has a price target of $20. Current year estimate on EPS consensus is $1.3.

Albany Molecular Research, Inc. has a Price to Earnings ratio of 19.75 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 2.08. For the Most Recent Fiscal Year, Albany Molecular Research, Inc. has a price to cash ratio of 21.91. For the Trailing twelve month period, company showed a Net Profit Margin of -12.3% and Return on Equity of the stock is 10.96%.

For Dividend Investing Stock Market Traders Albany Molecular Research, Inc. has a Dividend Yield of 0% with an Annual Dividend of $0. It has a Payout Ratio of 0 and the change in Dividend payout ratio is 0.

Albany Molecular Research Last issued its quarterly earnings results on Feb 21, 2017. The company reported $0.34 EPS for the quarter, missing the analyst consensus estimate by $ -0.14. Analyst had a consensus of $0.48. The company had revenue of $191.30 million for the quarter, compared to analysts expectations of $221.31 million. The companys revenue was up 51.3% compared to the same quarter last year.

Company has reported several Insider transactions to the SEC, on Dec 5, 2016, Anthony J Maddaluna (director) purchased 1,518 shares at 16.46 per share price.On Dec 1, 2016, Steven R Hagen (SVP Manufacturing & Pharmaceut) sold 9,000 shares at 16.71 per share price.On Nov 17, 2016, Lori M. Henderson (SVP, Secretary & Gen Counsel) sold 6,000 shares at 17.00 per share price.

Albany Molecular Research, Inc. (NASDAQ:AMRI) witnessed a decline in the market cap on Wednesday as its shares dropped 5.67% or 0.93 points. After the session commenced at $16.36, the stock reached the higher end at $16.37 while it hit a low of $15.37. With the volume soaring to 1,318,175 shares, the last trade was called at $15.46. The company has a 52-week high of $19.35. The company has a market cap of $663 million and there are 42,890,893 shares in outstanding. The 52-week low of the share price is $12.45.

Albany Molecular Research is an integrated provider of drug discovery and development, chemistry research and manufacturing services. They offer services traditionally provided by chemistry divisions within pharmaceutical and biotechnology companies, including drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. Recently, they expanded their service offerings to include commercial manufacturing through their strategic relationship with and investment in Organichem Corporation.


Add Comment